Please type a plus sign (+) inside this box —	\vdash
---	----------

Substituta	for form	14494	VR/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	•	•		• •
Sheet	1		of	

	Complete if Known	
Application Number	10/579,007	
Filing Date	Oct. 19, 2006	
First Named Inventor	Panicali et al.	
Group Art Unit	1633	
Examiner Name	Anne Marie Sabrina Wehbe	
Attorney Docket Number	701278	
Client Reference No.	E-088-2005/0-US-03	

U.S. PATENT DOCUMENTS							
		U.S. Patent Do	cument				
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
	AA	2008/0166367	A1	Panicali et al.	Jul 10, 2008		
							

FOREIGN PATENT DOCUMENTS							
		F	oreign Patent Docume	nt			
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Translation *
	AB	WO	01/24832	A2	Gabriele Pecher	Apr. 12, 2001	English abstract
	AC	WO	02/101075	A2	Millennium Pharmaceuticals	Dec. 19, 2002	
	AD	WO	03/085087	A2	Aventis Pasteur, Limited and Therion Biologics, Limited	Oct. 16,2003	
	ΑE	WO	03/106648	A2	Diadexus, Inc.	Dec. 24, 2003	

	OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *			
	AF	HODGE et al., Clinical Cancer Research, 9: 1837-1849 (2003)				
	AG	HODGE et al., Clinical Cancer Research, 59: 5800-5807 (1999)				
	АН	LIGTENBERG et al., Journal of Biological Chemistry, 265(10): 5573-5578 (1990)				
	ΑI	TAYLOR-PAPADIMITROU et al., Biochemica et Biophysica Acta, 1455: 301-313 (1999)				
	AJ	TSANG et al., Clinical Cancer Research, 11: 1597-1607 (2005)				
	AK	ZRIHAN-LICHT et al., European Journal of Biochemistry, 224(2): 787-795 (1994)				

Examiner Signature	D	Date Considered	

If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.